Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy

Annu Rev Pharmacol Toxicol. 2024 Jan 23:64:89-114. doi: 10.1146/annurev-pharmtox-051920-095416. Epub 2023 Sep 18.

Abstract

Today's challenge for precision medicine involves the integration of the impact of molecular clocks on drug pharmacokinetics, toxicity, and efficacy toward personalized chronotherapy. Meaningful improvements of tolerability and/or efficacy of medications through proper administration timing have been confirmed over the past decade for immunotherapy and chemotherapy against cancer, as well as for commonly used pharmacological agents in cardiovascular, metabolic, inflammatory, and neurological conditions. Experimental and human studies have recently revealed sexually dimorphic circadian drug responses. Dedicated randomized clinical trials should now aim to issue personalized circadian timing recommendations for daily medical practice, integrating innovative technologies for remote longitudinal monitoring of circadian metrics, statistical prediction of molecular clock function from single-timepoint biopsies, and multiscale biorhythmic mathematical modelling. Importantly, chronofit patients with a robust circadian function, who would benefit most from personalized chronotherapy, need to be identified. Conversely, nonchronofit patients could benefit from the emerging pharmacological class of chronobiotics targeting the circadian clock.

Keywords: between-subjects variability; chronopharmacology; chronotherapy; circadian rhythms; precision medicine; sex specificity.

Publication types

  • Review

MeSH terms

  • Chronotherapy
  • Circadian Clocks*
  • Circadian Rhythm
  • Female
  • Humans
  • Male
  • Neoplasms* / drug therapy
  • Pharmaceutical Preparations

Substances

  • Pharmaceutical Preparations